Fig. 1

High ADPGK expression is associated with poor oncologic outcomes. a Validation of ADPGK expression in clinical PCa samples by Western blotting (n = 4). b ADPGK expression status in the clinical samples assessed by immunohistochemistry (IHC). Scale bar = 100 μm. c PCa samples were divided into low and high ADPGK expression groups according to the IHC results. Scale bar = 100 μm. d Associations of ADPGK with different clinical features. e Kaplan‒Meier curves showing the association of ADPGK with BCR in 45 patients. f Multivariate Cox regression analyses of the relationship between parameters with BCR. Data are presented as the mean ± SD. **P < 0.01. ADPGK ADP-dependent glucokinase, N normal, T tumor, PCa prostate cancer, BPH benign prostate hyperplasia, GS Gleason score, SVI seminal vesicle invasion, PNI perineural invasion, HR hazard ratio, SD standard deviation, BCR biochemical recurrence, ADT androgen deprivation therapy, PSA prostate specific antigen, RARP robot-assisted laparoscopic radical prostatectomy